Drug intelligence / Profile preview

Infanrix hexa + Prevenar + Rotarix

Development stage
Unknown
Lead developer
GSK
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular, Oral
01

Overview

Infanrix hexa + Prevenar + Rotarix refers to the concomitant administration of three distinct pediatric vaccines. Infanrix hexa (GSK) is a hexavalent vaccine providing protection against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Haemophilus influenzae type b. Prevenar (Pfizer), specifically Prevenar 13, is a 13-valent pneumococcal conjugate vaccine targeting Streptococcus pneumoniae. Rotarix (GSK) is a live, attenuated oral vaccine against rotavirus. This regimen is commonly used in infant immunization schedules, typically at 2, 4, and 6 months of age. While co-administration is standard practice to reduce the number of visits, clinical data indicates a potential increase in the incidence of fever and febrile convulsions when Infanrix hexa and Prevenar 13 are administered together compared to Infanrix hexa alone.

Brand names
Prevenar 13Prevenar13Prevenar-13PCV13PCV-13PCV 13
Other names
DTaP-HepB-IPV-Hib + PCV13 + RV1
02

Targets

CPS (Streptococcus pneumoniae capsular polysaccharide)RIX4414 (Rotavirus antigens from live attenuated human rotavirus strain RIX4414)HBsAg (Hepatitis B surface antigen)Diphtheria toxin

Beyond the preview

Go deeper on Infanrix hexa + Prevenar + Rotarix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Infanrix hexa + Prevenar + Rotarix.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call